Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
HIV-positive people with a higher viral load over a longer period appear more likely to develop hepatocellular carcinoma.
Indicators of liver health improved at the same rate among those with cirrhosis who were cured of hep C regardless of their HIV status.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.
Scientists aren’t sure, but they know that the risk that a previous case of liver cancer will return remains high for those cured of hep C.
This is according to an analysis of multiple factors potentially related to a diabetes diagnosis in a large group of French people with HIV.
People who have a low CD4 count, have cirrhosis and take certain hep C drug regimens are less likely to be cured.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.
Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.